Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

BACKGROUND: Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (EGFRm+). Head-to-head clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Brückl, Wolfgang M., Reck, Martin, Griesinger, Frank, Schäfer, Harald, Kortsik, Cornelius, Gaska, Tobias, Rawluk, Justyna, Krüger, Stefan, Kokowski, Konrad, Budweiser, Stephan, Ficker, Joachim H., Hoffmann, Christopher, Schüler, Andrea, Laack, Eckart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111535/
https://www.ncbi.nlm.nih.gov/pubmed/33995597
http://dx.doi.org/10.1177/17588359211012361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111535/
https://www.ncbi.nlm.nih.gov/pubmed/33995597
http://dx.doi.org/10.1177/17588359211012361

Ejemplares similares